



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue application of:

HUANG *et al.*

Application No. 10/664,050

Filed September 17, 2003

For: METHOD FOR THE
SUPPRESSION OF VIRAL
GROWTH

Art Unit: 1651

Examiner: Irene Marx

Atty. Docket No. 2240-218200

Customer No.



Information Disclosure Statement

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement in order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the document which is listed on the attached Form PTO SB/08A and which the Examiner may deem relevant to patentability of the claims of the above-identified application.


In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the document and make it of record.

Applicant: Ru Chih HUANG et al.
Attorney's Doc. No.: 02240-218200

Please charge any necessary fee or credit any overpayment in connection with this
Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Date: 1/23/06


Ann S. Hobbs, Ph.D.
Registration No. 36,830
VENABLE LLP
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 344-4000
Telefax: (202) 344-8300

DOCS#716810

Please type a plus sign (+) inside this box →



JAN 23 2006

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet 1 of 2

Application Number	10/664,050
Filing Date	September 17, 2003
First Named Inventor	HUANG et al.
Group Art Unit	1651
Examiner Name	I. Marx
Attorney Docket Number	02240-218200

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	4,425,327		Moeller et al.	1/1984	
	2	4,880,637		Jordan	11/1989	
	3	5,008,294		Jordan et al.	4/1991	
	4	5,559,149		Clum et al.	9/1996	
	5	5,663,209		Huang et al.	9/1997	
	6	5,827,898		Khandwala et al.	10/1998	
	7	5,837,252		Sinnott et al.	11/1998	
	8	5,965,616		Wang et al.	10/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	9	Giza et al., A self-inducing runaway-replication plasmid expression system utilizing the Ro protein, Elsevier Science Publishers B.V. (Biomedical Division), Gene 78, 1989, pp. 73-84	
	10	Staal et al., Antioxidants Inhibits Stimulation of HIV Transcription, Aids Research and Human Retroviruses, 1993, vol. 9, No. 4, pp 299-306	
	11	Gnabre et al., Isolation of anti-HIV-1 lignans from <i>Larrea tridentate</i> counter-current chromatography, Journal of Chromatography A., 719, 1996, pp. 353-364	
	12	Gnabre et al., Characterization of Anti-HIV Lignans from <i>Larrea tridentate</i> , Tetrahedron, 1995, vol. 51, No. 45, pp. 12203-12210	
	13	Weislow et al., New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity, Journal of the National Cancer Institute, 1989, vol. 81, No. 8, pp. 577-586	
	14	Gnabre et al., Inhibition of Human Immunodeficiency Virus type 1 transcription and replication by DNA sequence-s-elective plant lignans, Proc. Natl. Acad. Sci. USA, 1995, vol. 92, pp. 11239-11243	
	15	Gisvold et al., Lignans from <i>Larrea divaricata</i> , Journal of Pharmaceutical Sciences, 1974, vol. 63, No. 12, pp. 1905-1907	

Examiner
SignatureDate
Considered

+

+

+

+

Complete if Known

Application Number	10/664,050
Filing Date	September 17, 2003
First Named Inventor	HUANG et al.
Group Art Unit	1651
Examiner Name	I. Marx
Attorney Docket Number	02240-218200

Application Number	10/664,050
Filing Date	September 17, 2003
First Named Inventor	HUANG et al.
Group Art Unit	1651
Examiner Name	I. Marx
Attorney Docket Number	02240-218200

Application Number	10/664,050
Filing Date	September 17, 2003
First Named Inventor	HUANG et al.
Group Art Unit	1651
Examiner Name	I. Marx
Attorney Docket Number	02240-218200

[illegible][illegible]

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	Perry et al., Synthesis of Lignans, I. Nordihydroguaiaretic Acid I, J. Org. Chem., 1972, vol. 37, No. 26, p., 4371-4376	

Date
ConsideredDate
Considered